CLAIM #2423 · AbbVie Inc (ABBV) · 2024Q2 earnings call · Jul 25, 2024 · due Dec 31, 2024
“So the $11 floor, again, was on an ex-IPR&D basis, where obviously with this guidance, ex-IPR&D, I think, we’re just a little bit over $11.40 and we’re certainly positioned to return to robust growth.”
Rob Michael · CEO
PENDING
graded after results covering Dec 31, 2024 are reported
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2024Q2 earnings call.